Arcus Biosciences, Inc. (RCUS) financial statements (2020 and earlier)

Company profile

Business Address 3928 POINT EDEN WAY
HAYWARD, CA 94545
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
12/31/2018
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments5871
Cash and cash equivalents5871
Receivables 0
Contract with customer, asset0 
Other undisclosed current assets135188
Total current assets:193259
Noncurrent Assets
Property, plant and equipment911
Long-term investments and receivables 1
Long-term investments 1
Restricted cash and investments00
Other noncurrent assets10
Other undisclosed noncurrent assets 3
Total noncurrent assets:1016
TOTAL ASSETS:203275
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities149
Accounts payable53
Accrued liabilities106
Deferred revenue7
Other liabilities12
Other undisclosed current liabilities 6
Total current liabilities:2317
Noncurrent Liabilities
Liabilities, other than long-term debt176
Deferred revenue12
Deferred rent credit44
Other liabilities12
Other undisclosed noncurrent liabilities 17
Total noncurrent liabilities:1723
Total liabilities:3940
Stockholders' equity
Stockholders' equity attributable to parent164235
Common stock00
Additional paid in capital369358
Accumulated other comprehensive income (loss)0(0)
Accumulated deficit(205)(123)
Total stockholders' equity:164235
TOTAL LIABILITIES AND EQUITY:203275

Income statement (P&L) ($ in millions)

12/31/2019
12/31/2018
Gross profit:158
Operating expenses(104)(63)
Operating loss:(89)(55)
Nonoperating income45
Net loss available to common stockholders, diluted:(85)(50)

Comprehensive Income ($ in millions)

12/31/2019
12/31/2018
Net loss:(85)(50)
Other comprehensive income (loss)0(0)
Comprehensive loss, net of tax, attributable to parent:(85)(50)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: